85305-87-9
Chemical Structure
Glucosylceramide (gaucher's spleen)
Synonym(s): Glucocerebrosides; Gaucher cerebroside; GluCers (gaucher's spleen)
- CAS No.: 85305-87-9
- Formula:N/A
- Molecular Weight:N/A
SMILES: O[C@H]1[C@@H]([C@H](O[C@H]([C@@H]1O)OC[C@H](NC([R])=O)[C@@H](/C=C/CCCCCCCCCCCCC)O)CO)O
Biological Activity: Glucosylceramide (Glucocerebrosides) (gaucher's spleen) is a glycosphingolipid and primary substrate of acid β-glycosidase, suppresses tyrosine phosphorylation of insulin receptor and IRS-1, disrupts insulin signaling cascade and triggers pancreatic β-cell dysfunction. Glucosylceramide (Gaucher's spleen) accumulates in rodents and induces obesity and insulin resistance, restores systemic glucose homeostasis and insulin sensitivity when synthesis is suppressed. Glucosylceramide (Gaucher's spleen) accumulates in the brain of chronic neuronopathic Gaucher disease mice with age and can be applied for research on insulin resistance, type 2 diabetes mellitus and chronic neuronopathic Gaucher disease[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Glucosylceramide (gaucher's spleen) | 98.0% | Glucosylceramide (Glucocerebrosides) (gaucher's spleen) is a glycosphingolipid and primary substrate of acid β-glycosidase, suppresses tyrosine phosphorylation of insulin receptor and IRS-1, disrupts insulin signaling cascade and triggers pancreatic β-cell dysfunction. Glucosylceramide (Gaucher's spleen) accumulates in rodents and induces obesity and insulin resistance, restores systemic glucose homeostasis and insulin sensitivity when synthesis is suppressed. Glucosylceramide (Gaucher's spleen) accumulates in the brain of chronic neuronopathic Gaucher disease mice with age and can be applied for research on insulin resistance, type 2 diabetes mellitus and chronic neuronopathic Gaucher disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Holland WL, et al. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocrine reviews. 2008 Jun;29(4):381-402. [Content Brief]
- [2]. Dai M, et al. Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease. PloS one. 2016;11(9):e0162367.
- [3]. Cahoon EB, et al. Analysis of Glucocerebrosides of Rye (Secale cereale L. cv Puma) Leaf and Plasma Membrane. Plant Physiol. 1991 Jan;95(1):58-68. [Content Brief]
